Literature DB >> 1551180

Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone.

L T Vlasveld1, B G Taal, B B Kroon, M P Gallee, S Rodenhuis.   

Abstract

A 44-year-old man who had achieved a complete remission of malignant peritoneal mesothelioma after the intraperitoneal administration of 25 mg/m2 mitoxantrone presented with clinical and radiological signs of intestinal obstruction suggestive of recurrent disease at about 2 years following the initial treatment. However, laparotomy revealed extensive adhesive fibrosis but no sign of malignant mesothelioma. The peritoneal complications of intraperitoneal cytostatic treatment are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551180     DOI: 10.1007/bf00686012

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  27 in total

1.  Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study.

Authors:  E A Eisenhauer; W K Evans; D Raghavan; M J Desmeules; N R Murray; R Stuart-Harris; K S Wilson
Journal:  Cancer Treat Rep       Date:  1986-08

Review 2.  Intraperitoneal chemotherapy: a review.

Authors:  D E Brenner
Journal:  J Clin Oncol       Date:  1986-07       Impact factor: 44.544

Review 3.  Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity.

Authors:  M Markman
Journal:  Cancer Treat Rev       Date:  1986-12       Impact factor: 12.111

4.  Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer.

Authors:  R F Ozols; R C Young; J L Speyer; P H Sugarbaker; R Greene; J Jenkins; C E Myers
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

5.  Elevation of CA 125 in patients with benign and malignant ascites.

Authors:  J F Bergmann; J M Bidart; M George; M Beaugrand; V G Levy; C Bohuon
Journal:  Cancer       Date:  1987-01-15       Impact factor: 6.860

6.  Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients.

Authors:  V C Gandhi; H M Humayun; T S Ing; J T Daugirdas; V R Jablokow; S Iwatsuki; W P Geis; J E Hano
Journal:  Arch Intern Med       Date:  1980-09

7.  The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients.

Authors:  D S Alberts; H S Chen; S Y Chang; Y M Peng
Journal:  Recent Results Cancer Res       Date:  1980

8.  Escalating dose regimen of intraperitoneal mitoxantrone: phase I study--clinical and pharmacokinetic evaluation.

Authors:  B Blöchl-Daum; H G Eichler; H Rainer; R Jakesz; H Salzer; G Steger; J Schüller; E Günther; B Proksch; G Ehninger
Journal:  Eur J Cancer Clin Oncol       Date:  1988-07

9.  Local and systemic toxicity resulting from large-volume ip administration of doxorubicin in the rat.

Authors:  C L Litterst; J M Collins; M C Lowe; S T Arnold; D M Powell; A M Guarino
Journal:  Cancer Treat Rep       Date:  1982-01

10.  Complications of extensive adhesion formation after intraperitoneal chemotherapy.

Authors:  M Markman; S Cleary; S B Howell; W E Lucas
Journal:  Surg Gynecol Obstet       Date:  1986-05
View more
  4 in total

Review 1.  Intracavitary therapies for mesothelioma.

Authors:  C F Verschraegen
Journal:  Curr Treat Options Oncol       Date:  2001-10

Review 2.  Successful surgical approach for a patient with encapsulating peritoneal sclerosis after hyperthermic intraperitoneal chemotherapy: a case report and literature review.

Authors:  Katsushi Takebayashi; Hiromichi Sonoda; Tomoharu Shimizu; Hiroyuki Ohta; Mitsuaki Ishida; Eiji Mekata; Yoshihiro Endo; Tohru Tani; Masaji Tani
Journal:  BMC Surg       Date:  2014-08-27       Impact factor: 2.102

3.  In Vivo Feasibility of Electrostatic Precipitation as an Adjunct to Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC).

Authors:  Tinatin Kakchekeeva; Cedric Demtröder; Nirmitha I Herath; Dominic Griffiths; Jared Torkington; Wiebke Solaß; Marie Dutreix; Marc A Reymond
Journal:  Ann Surg Oncol       Date:  2016-02-02       Impact factor: 5.344

4.  Sclerosing encapsulating peritonitis as a rare cause of intestinal obstruction after the treatment of peritoneal mesothelioma: a case report and review of the literature.

Authors:  Zhizhan Ni; Qing Chen; Chenshen Huang; Song Wang; Qi Huang
Journal:  Transl Cancer Res       Date:  2021-06       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.